A new experimental strategy for treating ischemia of the human myocardium is to use angiogenic growth factors to induce neovascularization. This approach is based upon recent findings showing that in the adult heart the genes encoding angiogenic growth factors and their receptors are expressed in areas surrounding ischemic myocardium, but at levels that are insufficient to provide robust formation of collaterals. Administration of angiogenic growth factors can be viewed as an amplification of a normal response of the myocardia to ischemia. Vascular endothelial growth factor (VEGF) serves as a major angiogenic factor in normal cardiac development, and its use in therapeutic angiogenesis is currently undergoing clinical evaluation. VEGF binds to two high affinity endothelial cell receptor, KDR and FLT1. The interaction of VEGF with KDR is dependent upon other cell surface molecules, in particular heparan sulfate proteoglycans (NSPG). Little information is available as to the mechanisms by which HSPGs allow for growth factor binding. My application proposes three Specific Aims for clarifying those mechanisms.
Specific Aim 1 tests the hypothesis that HSPGs interact with KDR in order to facilitate receptor dimerization and VEGF binding. The proposed experiments build upon previously obtained results that support this hypothesis.
Specific Aim 2 is directed at identifying the proteoglycan involved in VEGF binding to KDR. Experiments are proposed for testing whether a known pro teoglycan is responsible; or if not, for purifying the protein and identifying its amino acid sequence.
Specific Aim 3 is directed at testing whether the relevant HSPG participates in VEGF-induced signaling events. The rationale for this study relates to the recent information derived from the literature indicating that HSPGs participate in the signal transduction pathways by which cells respond to their extracellular environment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL067019-04
Application #
6700752
Study Section
Pathology A Study Section (PTHA)
Program Officer
Goldman, Stephen
Project Start
2001-03-05
Project End
2005-01-31
Budget Start
2004-02-02
Budget End
2005-01-31
Support Year
4
Fiscal Year
2004
Total Cost
$292,250
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Bonuccelli, Gloria; Sotgia, Federica; Frank, Philippe G et al. (2005) ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection. Am J Physiol Cell Physiol 288:C1402-10
Hotchkiss, Kylie A; Basile, Cheryl M; Spring, Simone C et al. (2005) TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. Exp Cell Res 305:133-44
Tao, Qi; Spring, Simone C; Terman, Bruce I (2005) Comparison of the signaling mechanisms by which VEGF, H2O2, and phosphatase inhibitors activate endothelial cell ERK1/2 MAP-kinase. Microvasc Res 69:36-44
Gong, Chunhong; Stoletov, Konstantin V; Terman, Bruce I (2004) VEGF treatment induces signaling pathways that regulate both actin polymerization and depolymerization. Angiogenesis 7:313-21
Stoletov, Konstantin V; Terman, Bruce I (2004) Bmx is a downstream Rap1 effector in VEGF-induced endothelial cell activation. Biochem Biophys Res Commun 320:70-5
Stoletov, Konstantin V; Gong, Chunhong; Terman, Bruce I (2004) Nck and Crk mediate distinct VEGF-induced signaling pathways that serve overlapping functions in focal adhesion turnover and integrin activation. Exp Cell Res 295:258-68
Tao, Qi; Spring, Simone C; Terman, Bruce I (2003) Characterization of a new alternatively spliced neuropilin-1 isoform. Angiogenesis 6:39-45
Spring, Simone C; Terman, Bruce I (2002) Identification of a syndecan 4 pseudogene. DNA Seq 13:353-7
Firestein, G S; Reifler, D; Richman, D et al. (1988) Rapid and reversible modulation of T4 (CD4) on monocytoid cells by phorbol myristate acetate: effect on HIV susceptibility. Cell Immunol 113:63-9